Vaxart Inc (VXRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vaxart Inc (VXRT) has a cash flow conversion efficiency ratio of -0.022x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.05 Million) by net assets ($94.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VXRT equity to assets ratio to measure how much of total assets are equity-financed.
Vaxart Inc - Cash Flow Conversion Efficiency Trend (1985–2025)
This chart illustrates how Vaxart Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check VXRT cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Vaxart Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vaxart Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tecogen Inc.
NYSE:TGEN
|
-0.120x |
|
Horizon Copper Corp.
V:HCU
|
-0.023x |
|
Clal Industries and Beverages Ltd
TA:CLBV
|
-0.001x |
|
Bastogi S.p.A
F:BAOA
|
0.002x |
|
Sangoma Technologies Corp
TO:STC
|
0.046x |
|
BlackRock Long-Term Municipal Advantage Trust
NYSE:BTA
|
0.021x |
|
DSC Investment Inc
KQ:241520
|
-0.040x |
|
Chunil Express
KO:000650
|
0.001x |
Annual Cash Flow Conversion Efficiency for Vaxart Inc (1985–2025)
The table below shows the annual cash flow conversion efficiency of Vaxart Inc from 1985 to 2025. For the full company profile with market capitalisation and key ratios, see Vaxart Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $87.80 Million | $7.71 Million | 0.088x | +111.57% |
| 2024-12-31 | $58.92 Million | $-44.76 Million | -0.760x | +37.67% |
| 2023-12-31 | $57.80 Million | $-70.45 Million | -1.219x | -42.22% |
| 2022-12-31 | $110.60 Million | $-94.78 Million | -0.857x | -168.60% |
| 2021-12-31 | $187.53 Million | $-59.83 Million | -0.319x | -65.78% |
| 2020-12-31 | $123.40 Million | $-23.75 Million | -0.192x | +80.96% |
| 2019-12-31 | $12.95 Million | $-13.09 Million | -1.011x | +21.93% |
| 2018-12-31 | $11.24 Million | $-14.55 Million | -1.295x | -141.11% |
| 2017-12-31 | $18.70 Million | $-10.04 Million | -0.537x | -75.92% |
| 2016-12-31 | $46.20 Million | $-14.10 Million | -0.305x | -120.95% |
| 2015-12-31 | $69.50 Million | $-9.60 Million | -0.138x | -263.74% |
| 2014-12-31 | $86.90 Million | $-3.30 Million | -0.038x | +81.42% |
| 2013-12-31 | $68.00 Million | $-13.90 Million | -0.204x | -0.29% |
| 2012-12-31 | $68.20 Million | $-13.90 Million | -0.204x | +20.88% |
| 2011-12-31 | $58.87 Million | $-15.17 Million | -0.258x | -139.08% |
| 2010-12-31 | $60.57 Million | $39.93 Million | 0.659x | +932.93% |
| 2009-12-31 | $97.41 Million | $6.22 Million | 0.064x | +140.99% |
| 2008-12-31 | $121.38 Million | $-18.90 Million | -0.156x | +14.68% |
| 2007-12-31 | $146.53 Million | $-26.74 Million | -0.183x | +53.70% |
| 2006-12-31 | $111.39 Million | $-43.91 Million | -0.394x | +28.89% |
| 2005-12-31 | $161.83 Million | $-89.71 Million | -0.554x | -1903.87% |
| 2004-12-31 | $284.32 Million | $8.74 Million | 0.031x | +30.12% |
| 2003-12-31 | $319.32 Million | $7.54 Million | 0.024x | -59.11% |
| 2002-12-31 | $189.03 Million | $10.92 Million | 0.058x | -55.03% |
| 2001-12-31 | $187.21 Million | $24.05 Million | 0.128x | +1.35% |
| 2000-12-31 | $77.39 Million | $9.81 Million | 0.127x | -68.34% |
| 1999-12-31 | $58.20 Million | $23.30 Million | 0.400x | +19.22% |
| 1998-12-31 | $54.20 Million | $18.20 Million | 0.336x | +199.30% |
| 1997-12-31 | $75.70 Million | $-25.60 Million | -0.338x | -569.63% |
| 1996-12-31 | $86.10 Million | $6.20 Million | 0.072x | -19.40% |
| 1995-12-31 | $69.40 Million | $6.20 Million | 0.089x | +1025.53% |
| 1994-12-31 | $51.80 Million | $-500.00K | -0.010x | -105.79% |
| 1993-12-31 | $18.00 Million | $3.00 Million | 0.167x | -20.11% |
| 1992-12-31 | $13.90 Million | $2.90 Million | 0.209x | +1675.18% |
| 1991-12-31 | $15.10 Million | $-200.00K | -0.013x | -132.05% |
| 1990-12-31 | $12.10 Million | $500.00K | 0.041x | -85.68% |
| 1989-12-31 | $9.70 Million | $2.80 Million | 0.289x | +1097.94% |
| 1988-12-31 | $8.30 Million | $200.00K | 0.024x | -81.63% |
| 1986-12-31 | $6.10 Million | $800.00K | 0.131x | -64.59% |
| 1985-12-31 | $2.70 Million | $1.00 Million | 0.370x | -- |
About Vaxart Inc
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; COVID-19 Vaccine, which is in Phas… Read more